Information Provided By:
Fly News Breaks for April 3, 2018
UTHR
Apr 3, 2018 | 07:33 EDT
Credit Suisse analyst Martin Auster upgraded United Therapeutics to Neutral from Underperform as he believes efficient downside valuation scenario suggests limited sustained downside risk below $95/share. A worst-case revenue outcome combined with long-term inefficient spending would be required to drive substantial downside from current levels, he contends. Auster lowered his price target on the shares to $108 from $115.
News For UTHR From the Last 2 Days
There are no results for your query UTHR